Jiadong Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiadong Wu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ayiguli Abulimiti
School of Public Health, Fujian Medical University, Fuzhou, China
2 shared publications - Beibei Rao
School of Public Health, Fujian Medical University, Fuzhou, China
2 shared publications - Bingtao Weng
Department of Big Data in Health Science, Zhejiang University School of Public Health and Department of Psychiatry, Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou China
2 shared publications - Hao Shang
School of Public Health, Fujian Medical University, Fuzhou, China
2 shared publications - Jia Rui
Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University
2 shared publications - Jiabing Wu
Anhui Provincial Center for Disease Control and Prevention, Hefei, 230601, China
2 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Hand, Foot, and Mouth Disease Surveillance in Anhui, After Introduction of the Enterovirus 71 Vaccine and During the COVID-19 Pandemic: Ecological Interrupted Time Series Study (Preprint)
BACKGROUND Routine surveillance is important for understanding hand, foot, and mouth disease (HFMD) after monovalent enterovirus 71 (EV71) vaccine introduction, but interpretation is difficult when etiologic typing is sparse and the COVID-19 pandemic overlaps with the postvaccine era. OBJECTIVE This study described surveillance-derived changes in HFMD burden and typed serotype composition in Anhui Province, China, after EV71 vaccine introduction and during the COVID-19 pandemic. METHODS We conducted a retrospective ecological surveillance study using HFMD records from January 2008 to December 2023. The primary analysis used negative-binomial interrupted time series (ITS) counterfactual models for all reported HFMD cases and typed EV71 monthly counts. Vaccine-era models were trained using data from January 2013 through May 2016; the previous specification covering January 2010 through May 2016 was retained as a sensitivity analysis. COVID-19–period models were trained using data from January 2008 through December 2019. Secondary analyses assessed spatial, temporal, and age patterns. Vaccine coverage histories, individual vaccination records, specimen submission metadata, and laboratory platform-change metadata were unavailable; therefore, models estimated calendar-based surveillance deviations rather than vaccine effectiveness. RESULTS Anhui reported 1,292,579 HFMD cases from 2008 to 2023, including 47,990 (3.7%) typed cases. EV71 declined from 45.8% (8479/18,534) of typed cases before vaccine introduction to 3.4% (578/16,930) during COVID-19, while other enteroviruses increased from 29.6% (5487/18,534) to 81.8% (13,848/16,930). There were 123 deaths from 2008 to 2023, corresponding to 9.52 deaths per 100,000 reported cases; no deaths were recorded from 2020 to 2023. In primary vaccine-era ITS models, typed EV71 counts remained below the predicted trajectory in 2017 to 2019: 470 observed vs 659 predicted cases (95% prediction interval [PI] 467-933) in 2017, 181 vs 531 (95% PI 379-798) in 2018, and 63 vs 427 (95% PI 305-662) in 2019. All reported HFMD cases were not uniformly below the vaccine-era counterfactual. During the COVID-19 pandemic, all reported HFMD cases remained below prediction through 2023, with the largest relative difference in 2022 (28,385 observed vs 175,601 predicted; 95% PI 111,465-268,202). The proportion of reported children aged ≥4 years increased from 19% (50,503/266,132) during 2017 to 2019 to 29.1% (44,133/151,795) during 2021 to 2023 (odds ratio 1.75, 95% CI 1.72-1.78; P<.001). CONCLUSIONS Typed EV71 surveillance signals declined after EV71 vaccine introduction, and overall HFMD burden was strongly disrupted during the COVID-19 pandemic. However, sparse typing, unavailable vaccination and testing policy metadata, and the aggregated other enteroviruses category limit causal interpretation. These findings should be read as surveillance signals, not as direct estimates of population-level serotype replacement or individual-level vaccine protection.
- 28 April 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessHand, Foot, and Mouth Disease Surveillance in Anhui, After Introduction of the Enterovirus 71 Vaccine and During the COVID-19 Pandemic: Ecological Interrupted Time Series Study (Preprint)
BACKGROUND Routine surveillance is important for understanding hand, foot, and mouth disease (HFMD) after monovalent enterovirus 71 (EV71) vaccine introduction, but interpretation is difficult when etiologic typing is sparse and the COVID-19 pandemic overlaps with the postvaccine era. OBJECTIVE This study described surveillance-derived changes in HFMD burden and typed serotype composition in Anhui Province, China, after EV71 vaccine introduction and during the COVID-19 pandemic. METHODS We conducted a retrospective ecological surveillance study using HFMD records from January 2008 to December 2023. The primary analysis used negative-binomial interrupted time series (ITS) counterfactual models for all reported HFMD cases and typed EV71 monthly counts. Vaccine-era models were trained using data from January 2013 through May 2016; the previous specification covering January 2010 through May 2016 was retained as a sensitivity analysis. COVID-19–period models were trained using data from January 2008 through December 2019. Secondary analyses assessed spatial, temporal, and age patterns. Vaccine coverage histories, individual vaccination records, specimen submission metadata, and laboratory platform-change metadata were unavailable; therefore, models estimated calendar-based surveillance deviations rather than vaccine effectiveness. RESULTS Anhui reported 1,292,579 HFMD cases from 2008 to 2023, including 47,990 (3.7%) typed cases. EV71 declined from 45.8% (8479/18,534) of typed cases before vaccine introduction to 3.4% (578/16,930) during COVID-19, while other enteroviruses increased from 29.6% (5487/18,534) to 81.8% (13,848/16,930). There were 123 deaths from 2008 to 2023, corresponding to 9.52 deaths per 100,000 reported cases; no deaths were recorded from 2020 to 2023. In primary vaccine-era ITS models, typed EV71 counts remained below the predicted trajectory in 2017 to 2019: 470 observed vs 659 predicted cases (95% prediction interval [PI] 467-933) in 2017, 181 vs 531 (95% PI 379-798) in 2018, and 63 vs 427 (95% PI 305-662) in 2019. All reported HFMD cases were not uniformly below the vaccine-era counterfactual. During the COVID-19 pandemic, all reported HFMD cases remained below prediction through 2023, with the largest relative difference in 2022 (28,385 observed vs 175,601 predicted; 95% PI 111,465-268,202). The proportion of reported children aged ≥4 years increased from 19% (50,503/266,132) during 2017 to 2019 to 29.1% (44,133/151,795) during 2021 to 2023 (odds ratio 1.75, 95% CI 1.72-1.78; P<.001). CONCLUSIONS Typed EV71 surveillance signals declined after EV71 vaccine introduction, and overall HFMD burden was strongly disrupted during the COVID-19 pandemic. However, sparse typing, unavailable vaccination and testing policy metadata, and the aggregated other enteroviruses category limit causal interpretation. These findings should be read as surveillance signals, not as direct estimates of population-level serotype replacement or individual-level vaccine protection.
- Open Access
- 28 April 2026
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 12, e99663
Hand, Foot, and Mouth Disease Surveillance in Anhui, China After Enterovirus 71 Vaccine Introduction and During COVID-19: Ecological Interrupted Time-Series Study (Preprint)
Background: Routine surveillance is important for understanding hand, foot, and mouth disease (HFMD) after monovalent enterovirus 71 (EV71) vaccine introduction, but interpretation is difficult when etiologic typing is sparse and the COVID-19 pandemic overlaps with the postvaccine era. Objective: This study described surveillance-derived changes in HFMD burden and typed serotype composition in Anhui Province, China, after EV71 vaccine introduction and during the COVID-19 pandemic. Methods: We conducted a retrospective ecological surveillance study using HFMD records from January 2008 to December 2023. The primary analysis used negative-binomial interrupted time series (ITS) counterfactual models for all reported HFMD cases and typed EV71 monthly counts. Vaccine-era models were trained using data from January 2013 through May 2016; the previous specification covering January 2010 through May 2016 was retained as a sensitivity analysis. COVID-19–period models were trained using data from January 2008 through December 2019. Secondary analyses assessed spatial, temporal, and age patterns. Vaccine coverage histories, individual vaccination records, specimen submission metadata, and laboratory platform-change metadata were unavailable; therefore, models estimated calendar-based surveillance deviations rather than vaccine effectiveness. Results: Anhui reported 1,292,579 HFMD cases from 2008 to 2023, including 47,990 (3.7%) typed cases. EV71 declined from 45.8% (8479/18,534) of typed cases before vaccine introduction to 3.4% (578/16,930) during COVID-19, while other enteroviruses increased from 29.6% (5487/18,534) to 81.8% (13,848/16,930). There were 123 deaths from 2008 to 2023, corresponding to 9.52 deaths per 100,000 reported cases; no deaths were recorded from 2020 to 2023. In primary vaccine-era ITS models, typed EV71 counts remained below the predicted trajectory in 2017 to 2019: 470 observed vs 659 predicted cases (95% prediction interval [PI] 467-933) in 2017, 181 vs 531 (95% PI 379-798) in 2018, and 63 vs 427 (95% PI 305-662) in 2019. All reported HFMD cases were not uniformly below the vaccine-era counterfactual. During the COVID-19 pandemic, all reported HFMD cases remained below prediction through 2023, with the largest relative difference in 2022 (28,385 observed vs 175,601 predicted; 95% PI 111,465-268,202). The proportion of reported children aged ≥4 years increased from 19% (50,503/266,132) during 2017 to 2019 to 29.1% (44,133/151,795) during 2021 to 2023 (odds ratio 1.75, 95% CI 1.72-1.78; P<.001). Conclusions: Typed EV71 surveillance signals declined after EV71 vaccine introduction, and overall HFMD burden was strongly disrupted during the COVID-19 pandemic. However, sparse typing, unavailable vaccination and testing policy metadata, and the aggregated other enteroviruses category limit causal interpretation. These findings should be read as surveillance signals, not as direct estimates of population-level serotype replacement or individual-level vaccine protection.
- 28 April 2026
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 12, e99663
Open AccessHand, Foot, and Mouth Disease Surveillance in Anhui, China After Enterovirus 71 Vaccine Introduction and During COVID-19: Ecological Interrupted Time-Series Study (Preprint)
Background: Routine surveillance is important for understanding hand, foot, and mouth disease (HFMD) after monovalent enterovirus 71 (EV71) vaccine introduction, but interpretation is difficult when etiologic typing is sparse and the COVID-19 pandemic overlaps with the postvaccine era. Objective: This study described surveillance-derived changes in HFMD burden and typed serotype composition in Anhui Province, China, after EV71 vaccine introduction and during the COVID-19 pandemic. Methods: We conducted a retrospective ecological surveillance study using HFMD records from January 2008 to December 2023. The primary analysis used negative-binomial interrupted time series (ITS) counterfactual models for all reported HFMD cases and typed EV71 monthly counts. Vaccine-era models were trained using data from January 2013 through May 2016; the previous specification covering January 2010 through May 2016 was retained as a sensitivity analysis. COVID-19–period models were trained using data from January 2008 through December 2019. Secondary analyses assessed spatial, temporal, and age patterns. Vaccine coverage histories, individual vaccination records, specimen submission metadata, and laboratory platform-change metadata were unavailable; therefore, models estimated calendar-based surveillance deviations rather than vaccine effectiveness. Results: Anhui reported 1,292,579 HFMD cases from 2008 to 2023, including 47,990 (3.7%) typed cases. EV71 declined from 45.8% (8479/18,534) of typed cases before vaccine introduction to 3.4% (578/16,930) during COVID-19, while other enteroviruses increased from 29.6% (5487/18,534) to 81.8% (13,848/16,930). There were 123 deaths from 2008 to 2023, corresponding to 9.52 deaths per 100,000 reported cases; no deaths were recorded from 2020 to 2023. In primary vaccine-era ITS models, typed EV71 counts remained below the predicted trajectory in 2017 to 2019: 470 observed vs 659 predicted cases (95% prediction interval [PI] 467-933) in 2017, 181 vs 531 (95% PI 379-798) in 2018, and 63 vs 427 (95% PI 305-662) in 2019. All reported HFMD cases were not uniformly below the vaccine-era counterfactual. During the COVID-19 pandemic, all reported HFMD cases remained below prediction through 2023, with the largest relative difference in 2022 (28,385 observed vs 175,601 predicted; 95% PI 111,465-268,202). The proportion of reported children aged ≥4 years increased from 19% (50,503/266,132) during 2017 to 2019 to 29.1% (44,133/151,795) during 2021 to 2023 (odds ratio 1.75, 95% CI 1.72-1.78; P<.001). Conclusions: Typed EV71 surveillance signals declined after EV71 vaccine introduction, and overall HFMD burden was strongly disrupted during the COVID-19 pandemic. However, sparse typing, unavailable vaccination and testing policy metadata, and the aggregated other enteroviruses category limit causal interpretation. These findings should be read as surveillance signals, not as direct estimates of population-level serotype replacement or individual-level vaccine protection.
- Open Access
- 22 February 2023
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 9, e40552
Changes in Mobile Health Apps Usage Before and After the COVID-19 Outbreak in China: Semilongitudinal Survey
Background: Mobile health (mHealth) apps are rapidly emerging technologies in China due to strictly controlled medical needs during the COVID-19 pandemic while continuing essential services for chronic diseases. However, there have been no large-scale, systematic efforts to evaluate relevant apps. Objective: We aim to provide a landscape of mHealth apps in China by describing and comparing digital health concerns before and after the COVID-19 outbreak, including mHealth app data flow and user experience, and analyze the impact of COVID-19 on mHealth apps. Methods: We conducted a semilongitudinal survey of 1593 mHealth apps to study the app data flow and clarify usage changes and influencing factors. We selected mHealth apps in app markets, web pages from the Baidu search engine, the 2018 top 100 hospitals with internet hospitals, and online shopping sites with apps that connect to smart devices. For user experience, we recruited residents from a community in southeastern China from October 2019 to November 2019 (before the outbreak) and from June 2020 to August 2020 (after the outbreak) comparing the attention of the population to apps. We also examined associations between app characteristics, functions, and outcomes at specific quantiles of distribution in download changes using quantile regression models. Results: Rehabilitation medical support was the top-ranked functionality, with a median 1.44 million downloads per app prepandemic and a median 2.74 million downloads per app postpandemic. Among the top 10 functions postpandemic, 4 were related to maternal and child health: pregnancy preparation (ranked second; fold change 4.13), women's health (ranked fifth; fold change 5.16), pregnancy (ranked sixth; fold change 5.78), and parenting (ranked tenth; fold change 4.03). Quantile regression models showed that rehabilitation (P75, P90), pregnancy preparation (P90), bodybuilding (P50, P90), and vaccination (P75) were positively associated with an increase in downloads after the outbreak. In the user experience survey, the attention given to health information (prepandemic: 249/375, 66.4%; postpandemic: 146/178, 82.0%; P=.006) steadily increased after the outbreak. Conclusions: mHealth apps are an effective health care approach gaining in popularity among the Chinese population following the COVID-19 outbreak. This research provides direction for subsequent mHealth app development and promotion in the postepidemic era, supporting medical model reformation in China as a reference, which may provide new avenues for designing and evaluating indirect public health interventions such as health education and health promotion.
- 22 February 2023
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 9, e40552
Open AccessChanges in Mobile Health Apps Usage Before and After the COVID-19 Outbreak in China: Semilongitudinal Survey
Background: Mobile health (mHealth) apps are rapidly emerging technologies in China due to strictly controlled medical needs during the COVID-19 pandemic while continuing essential services for chronic diseases. However, there have been no large-scale, systematic efforts to evaluate relevant apps. Objective: We aim to provide a landscape of mHealth apps in China by describing and comparing digital health concerns before and after the COVID-19 outbreak, including mHealth app data flow and user experience, and analyze the impact of COVID-19 on mHealth apps. Methods: We conducted a semilongitudinal survey of 1593 mHealth apps to study the app data flow and clarify usage changes and influencing factors. We selected mHealth apps in app markets, web pages from the Baidu search engine, the 2018 top 100 hospitals with internet hospitals, and online shopping sites with apps that connect to smart devices. For user experience, we recruited residents from a community in southeastern China from October 2019 to November 2019 (before the outbreak) and from June 2020 to August 2020 (after the outbreak) comparing the attention of the population to apps. We also examined associations between app characteristics, functions, and outcomes at specific quantiles of distribution in download changes using quantile regression models. Results: Rehabilitation medical support was the top-ranked functionality, with a median 1.44 million downloads per app prepandemic and a median 2.74 million downloads per app postpandemic. Among the top 10 functions postpandemic, 4 were related to maternal and child health: pregnancy preparation (ranked second; fold change 4.13), women's health (ranked fifth; fold change 5.16), pregnancy (ranked sixth; fold change 5.78), and parenting (ranked tenth; fold change 4.03). Quantile regression models showed that rehabilitation (P75, P90), pregnancy preparation (P90), bodybuilding (P50, P90), and vaccination (P75) were positively associated with an increase in downloads after the outbreak. In the user experience survey, the attention given to health information (prepandemic: 249/375, 66.4%; postpandemic: 146/178, 82.0%; P=.006) steadily increased after the outbreak. Conclusions: mHealth apps are an effective health care approach gaining in popularity among the Chinese population following the COVID-19 outbreak. This research provides direction for subsequent mHealth app development and promotion in the postepidemic era, supporting medical model reformation in China as a reference, which may provide new avenues for designing and evaluating indirect public health interventions such as health education and health promotion.
- Open Access
- 27 June 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Changes in Mobile Health Apps Usage Before and After the COVID-19 Outbreak in China: Semilongitudinal Survey (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Mobile health (mHealth) apps are rapidly emerging technologies in China due to strictly controlled medical needs during the COVID-19 pandemic while continuing essential services for chronic diseases. However, there have been no large-scale, systematic efforts to evaluate relevant apps. Objective: We aim to provide a landscape of mHealth apps in China by describing and comparing digital health concerns before and after the COVID-19 outbreak, including mHealth app data flow and user experience, and analyze the impact of COVID-19 on mHealth apps. Methods: We conducted a semilongitudinal survey of 1593 mHealth apps to study the app data flow and clarify usage changes and influencing factors. We selected mHealth apps in app markets, web pages from the Baidu search engine, the 2018 top 100 hospitals with internet hospitals, and online shopping sites with apps that connect to smart devices. For user experience, we recruited residents from a community in southeastern China from October 2019 to November 2019 (before the outbreak) and from June 2020 to August 2020 (after the outbreak) comparing the attention of the population to apps. We also examined associations between app characteristics, functions, and outcomes at specific quantiles of distribution in download changes using quantile regression models. Results: Rehabilitation medical support was the top-ranked functionality, with a median 1.44 million downloads per app prepandemic and a median 2.74 million downloads per app postpandemic. Among the top 10 functions postpandemic, 4 were related to maternal and child health: pregnancy preparation (ranked second; fold change 4.13), women's health (ranked fifth; fold change 5.16), pregnancy (ranked sixth; fold change 5.78), and parenting (ranked tenth; fold change 4.03). Quantile regression models showed that rehabilitation (P75, P90), pregnancy preparation (P90), bodybuilding (P50, P90), and vaccination (P75) were positively associated with an increase in downloads after the outbreak. In the user experience survey, the attention given to health information (prepandemic: 249/375, 66.4%; postpandemic: 146/178, 82.0%; P=.006) steadily increased after the outbreak. Conclusions: mHealth apps are an effective health care approach gaining in popularity among the Chinese population following the COVID-19 outbreak. This research provides direction for subsequent mHealth app development and promotion in the postepidemic era, supporting medical model reformation in China as a reference, which may provide new avenues for designing and evaluating indirect public health interventions such as health education and health promotion. Trial Registration:
- 27 June 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessChanges in Mobile Health Apps Usage Before and After the COVID-19 Outbreak in China: Semilongitudinal Survey (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Mobile health (mHealth) apps are rapidly emerging technologies in China due to strictly controlled medical needs during the COVID-19 pandemic while continuing essential services for chronic diseases. However, there have been no large-scale, systematic efforts to evaluate relevant apps. Objective: We aim to provide a landscape of mHealth apps in China by describing and comparing digital health concerns before and after the COVID-19 outbreak, including mHealth app data flow and user experience, and analyze the impact of COVID-19 on mHealth apps. Methods: We conducted a semilongitudinal survey of 1593 mHealth apps to study the app data flow and clarify usage changes and influencing factors. We selected mHealth apps in app markets, web pages from the Baidu search engine, the 2018 top 100 hospitals with internet hospitals, and online shopping sites with apps that connect to smart devices. For user experience, we recruited residents from a community in southeastern China from October 2019 to November 2019 (before the outbreak) and from June 2020 to August 2020 (after the outbreak) comparing the attention of the population to apps. We also examined associations between app characteristics, functions, and outcomes at specific quantiles of distribution in download changes using quantile regression models. Results: Rehabilitation medical support was the top-ranked functionality, with a median 1.44 million downloads per app prepandemic and a median 2.74 million downloads per app postpandemic. Among the top 10 functions postpandemic, 4 were related to maternal and child health: pregnancy preparation (ranked second; fold change 4.13), women's health (ranked fifth; fold change 5.16), pregnancy (ranked sixth; fold change 5.78), and parenting (ranked tenth; fold change 4.03). Quantile regression models showed that rehabilitation (P75, P90), pregnancy preparation (P90), bodybuilding (P50, P90), and vaccination (P75) were positively associated with an increase in downloads after the outbreak. In the user experience survey, the attention given to health information (prepandemic: 249/375, 66.4%; postpandemic: 146/178, 82.0%; P=.006) steadily increased after the outbreak. Conclusions: mHealth apps are an effective health care approach gaining in popularity among the Chinese population following the COVID-19 outbreak. This research provides direction for subsequent mHealth app development and promotion in the postepidemic era, supporting medical model reformation in China as a reference, which may provide new avenues for designing and evaluating indirect public health interventions such as health education and health promotion. Trial Registration: